Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 25Rituximab 18fludarabine phosphate 15Radiotherapy 13Methotrexate 13Peripheral Blood Stem Cell Transplantation 12Filgrastim 12Cytarabine 12Vincristine 11Melphalan 10Cyclosporine 10Busulfan 10Antilymphocyte Serum 10Exercise 9Doxorubicin 9Prednisone 7Mycophenolic Acid 7Magnetic Resonance Spectroscopy 7Etoposide 7Early Intervention, Educational 7Whole-Body Irradiation 6Surveys and Questionnaires 6Prednisolone 6Palliative Care 6Methods 6Leucovorin 6Educational Status 6Blood Specimen Collection 6Dexamethasone 5pegylated granulocyte colony-stimulating factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Lymphoma × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00389506 2012-03-16

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase NA Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡